Cantargia
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases. The company's innovative approach centers around the IL1RAP molecule, which is found on cancer cells and is involved in disease-causing inflammation. Cantargia's drug candidates, such as Nadunolimab and CAN10, aim to provide new treatment options for serious and debilitating diseases. The company operates primarily through strategic partnerships and has a strong intellectual property portfolio with over 100 patents globally.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueIncludes drugs targeting cancer cells, such as Nadunolimab.
Includes treatments like CAN10 for autoimmune diseases.
Collaborations for drug development and commercialization.
Customers
Cantargia's customers primarily include pharmaceutical companies and healthcare providers seeking advanced treatments for cancer and autoimmune diseases. The company's strategic partnerships, such as the one with Otsuka Pharmaceuticals, highlight its focus on collaboration for drug development and commercialization. Healthcare providers benefit from Cantargia's innovative therapies, which address unmet medical needs in oncology and immunology. The company's focus on targeted antibody-based treatments attracts interest from entities looking to enhance their therapeutic offerings in these areas.
They partner with Cantargia for innovative drug development.
They use Cantargia's therapies to treat cancer and autoimmune diseases.
They collaborate on drug development and commercialization.
Strategy
Cantargia's strategic priorities include advancing its pipeline of antibody-based therapies, particularly Nadunolimab and CAN10, through clinical trials and towards market registration. The company aims to strengthen its position in the oncology and immunology sectors by leveraging strategic partnerships and expanding its global presence. Cantargia is focused on maintaining a robust intellectual property portfolio to protect its innovations and create competitive barriers. The company is also committed to operational excellence and disciplined execution to maximize shareholder value and achieve long-term growth.
To achieve market registration and address unmet medical needs.
To expand global market access and enhance drug development.
To protect innovations and create competitive barriers.
Geography
Q4/2025Cantargia is headquartered in Lund, Sweden, and operates primarily through partnerships with global pharmaceutical companies. The company has a significant presence in Japan, where it has generated substantial revenue through its partnership with Otsuka Pharmaceuticals. Cantargia's strategic focus on international collaborations allows it to leverage global expertise and market access. The company's geographic strategy is centered around expanding its reach in key markets for oncology and immunology therapies.
Risks
Cantargia faces significant risks inherent in the biotech industry, including the high cost and uncertainty of drug development. The company is exposed to technological risks, such as insufficient efficacy or intolerable side effects of its drug candidates. Regulatory challenges and the need for successful clinical trials add to the complexity. Additionally, Cantargia's reliance on strategic partnerships introduces risks related to collaboration dynamics and milestone achievements. Market competition and changes in healthcare regulations also pose potential threats to the company's growth and profitability.
- Technological risks in drug developmentImpact: CriticalLikelihood: Medium
Potential for insufficient efficacy or intolerable side effects.
- Regulatory challengesImpact: HighLikelihood: Medium
Need for successful clinical trials and approvals.
- Reliance on strategic partnershipsImpact: HighLikelihood: Medium
Dependency on partners for milestone achievements and commercialization.
Accounting
Judgemental itemsSignificant impact on reported revenue due to timing and conditions.
Impact: high
Affects operating expenses and financial results.
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
BioArctic
BIOA-B · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Hansa Biopharma
HNSA · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
Candel Therapeutics, Inc.
CADL · Biological Products, (No Diagnostic Substances)
Adlai Nortye Group Ltd.
ANL · Pharmaceutical Preparations
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
NuCana plc
NCNA · Pharmaceutical Preparations
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer medicines based on its ProTide phosphoramidate chemistry platform.
Last updated: 24/09/2026